Accession Number: | 0001209191-21-057275 |
Date: | 2021-09-21 |
Issuer: | IMPEL NEUROPHARMA INC (IMPL) |
Original Submission Date: |
SHREWSBURY STEPHEN B
C/O IMPEL NEUROPHARMA, INC.
201 ELLIOTT AVE. W, ST. 260
SEATTLE, WA 98119
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|---|---|---|---|---|---|---|---|---|
COMMON STOCK | 2021-09-21 | M | 14,780 | a | $1.97 | 14,780 | direct | ||
COMMON STOCK | 2021-09-21 | M | 4,650 | a | $2.46 | 19,430 | direct | ||
COMMON STOCK | 2021-09-21 | M | 53,954 | a | $2.95 | 73,384 | direct |
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
STOCK OPTION (RIGHT TO BUY) | 1.97 | 2021-09-21 | deemed execution date | M | 14,780 (d) | 2027-10-17 | common stock 14,780 | $1.97 | 0 | direct | ||
STOCK OPTION (RIGHT TO BUY) | 2.46 | 2021-09-21 | deemed execution date | M | 4,650 (d) | 2028-03-08 | common stock 4,650 | $2.46 | 541 | direct | ||
STOCK OPTION (RIGHT TO BUY) | 2.95 | 2021-09-21 | deemed execution date | M | 53,954 (d) | 2029-02-07 | common stock 53,954 | $2.95 | 29,587 | direct |
ID | footnote |
---|---|
f1 | the option is 100% vested and exercisable. |
f2 | the option vested as to 25% of the total shares on february 13, 2019, then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested and exercisable on february 13, 2022, subject to the reporting person's provision of service to the issuer on each vesting date. |
f3 | the option vested as to 25% of the total shares on february 8, 2020, then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested and exercisable on february 8, 2023, subject to the reporting person's provision of service to the issuer on each vesting date. |